Mitotic mitoARCUS editing for MELAS m.3243A>G heteroplasmy shift

For MELAS patients carrying the pathogenic m.3243A>G heteroplasmy, mitochondrial-targeted gene editing via mitoARCUS or other compact nucleases offers the most mechanistically precise intervention because it can selectively eliminate mutant genomes and allow wild-type copies to repopulate without changing nuclear DNA.

The mitoARCUS platform (Shoop et al., Nature Metabolism 2023, DOI:10.1038/s42255-023-00932-6) cleaves m.3243G-containing mtDNA and permits wild-type mtDNA to repopulate, improving mitochondrial protein expression and respiration in xenograft models. Complementary base-editing and heteroplasmy-shifting studies (Joore et al., PLoS Biol. 2025, DOI:10.1371/journal.pbio.3003207) show that programmable steamlining of mtDNA can reduce mutant load to below phenotypic thresholds, aligning with PLOS Biology modeling of patient-derived MELAS cells. These tools thus match the loss-of-function nature of this tRNA mutation while respecting mitochondrial genetics.

Human payload delivery remains the biggest hurdle: mito-specific nucleases and editors still rely on AAV or similar vectors whose biodistribution in central nervous system and cardiac tissue is unsettled, and the exact heteroplasmy threshold for symptomatic reversal in each tissue is patient-specific. Translational work must carefully monitor mtDNA copy number drift and off-target indels inside the mitochondrial genome before proclaiming a clinically validated allele-specific therapy.